Discovery's Surfaxin Survival Benefit Continues Through One Year of Life

Discovery Laboratories has reported additional long-term clinical data from its two Surfaxin Phase III clinical trials to treat respiratory distress syndrome (RDS) in premature infants, SELECT and STAR.

The data show that premature infants treated with Surfaxin (lucinactant) experienced a survival benefit through one year of life, corrected age compared to those treated with the currently available animal-derived surfactants (Survanta and Curosurf). These findings build upon the statistically significant pooled data, which demonstrated that premature infants treated with Surfaxin experienced a survival benefit at 36 weeks postmenstrual age versus animal-derived surfactants.

The additional long-term clinical data were derived from a pooled analysis that combined data from the SELECT and STAR trials. This analysis was performed to determine the long-term outcomes including mortality and morbidity at one year of life, corrected age for Surfaxin versus the leading animal-derived surfactants, Survanta and Curosurf. The pooled Surfaxin data showed significantly improved survival compared to the combined data from the two animal-derived surfactants.